As previously reported, Evercore ISI upgraded Health Catalyst to Outperform from In Line with a price target of $11, up from $9. The Street is now “properly modelling” 16% Professional Services growth through FY25 and hospitals’ financial outlooks are now showing more persistent inflection with a particular uptick in IT demand for data/analytics, which “bodes well” for a second half of 2024 reacceleration in Tech revenues, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HCAT:
- Health Catalyst price target raised to $12 from $11 at Piper Sandler
- Health Catalyst to Participate in Upcoming Investor Conference
- Health Catalyst just upgraded at JPMorgan, here’s why
- Health Catalyst management to meet with BTIG
- Health Catalyst to Participate in Upcoming Investor Conferences
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue